A Phase II Study Of The Weekly Administration Of Docetaxel In Combination With Ther Epidermal Growth Factor Receptor Inhibitor OSI-774 In Recurrent And/Or Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2016
At a glance
- Drugs Docetaxel (Primary) ; Erlotinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 13 Jun 2011 Planned end date changed from 1 Sep 2013 to 1 Apr 2015 as reported by ClinicalTrials.gov.
- 13 Jan 2011 Planned end date (Mar 2007) added as reported by ClinicalTrials.gov.
- 02 Mar 2010 Actual patient number (39) added as reported by ClinicalTrials.gov.